Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $205M

Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the completion of the sale of Cyprium's Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million. Fortress expects to receive over $100 million from this transaction, which will enhance its financial flexibility for business development. Additionally, Fortress has secured three FDA approvals for its products in the past 15 months and sold its subsidiary Checkpoint Therapeutics to Sun Pharma. Cyprium will also receive tiered royalties and sales milestones from Sentynl Therapeutics related to ZYCUBO.